–News Direct–
Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) chief executive Dr Markku Jalkanen speaks to Thomas Warner from Proactive London after the clinical-stage biopharmaceutical company announced it has initiated Phase 2 of its BEXMAB Study of Bexmarilimab in HMA-failed myelodysplastic syndrome (MDS).
MDS is a group of bone marrow disorders that results in an inability to produce enough healthy blood cells.
Jalkanen starts by giving a brief summary of the company's hope for the BEXMAB study, before going on to reveal more information about its second phase.
He highlights the significant advantage to Faron of the relatively small size of the next phase of the study, which saves the company money at a time when many of its competitors are suffering financially – something he describes as a "a big relief for all of us."
He concludes by giving an overview of the company's financial position, highlighting the 7.1 million raised in late October in a share offering. He adds that "very intense" discussions with potential partners are ongoing.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
View source version on newsdirect.com: https://newsdirect.com/news/faron-pharmaceuticals-initiates-second-phase-of-bexmab-study-510836536
Faron Pharmaceuticals Oy
COMTEX_443042365/2655/2023-11-06T12:36:01
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Endowment Lock journalist was involved in the writing and production of this article.